牛牛AI助理已提取核心訊息
Merck & Co. Inc. officer Robert M. Davis is set to sell 85,021 shares of the company's common stock on February 14, 2024, according to a recent filing. The shares, valued at an aggregate market value of $10,661,573.89, were acquired on the same date through the exercise of options under a registered plan. The transaction involves the payment of cash to the issuer for the securities. This sale follows a previous transaction in the past three months where Davis sold 150,000 shares for a total gross proceed of $18,872,130.
Merck & Co. Inc. officer Robert M. Davis is set to sell 85,021 shares of the company's common stock on February 14, 2024, according to a recent filing. The shares, valued at an aggregate market value of $10,661,573.89, were acquired on the same date through the exercise of options under a registered plan. The transaction involves the payment of cash to the issuer for the securities. This sale follows a previous transaction in the past three months where Davis sold 150,000 shares for a total gross proceed of $18,872,130.
默沙東公司根據最近的一份文件，公司高管羅伯特·戴維斯定於2024年2月14日出售該公司85,021股普通股。這些股票的總市值爲10,661,573.89美元，於同日通過行使註冊計劃下的期權收購。該交易涉及向發行人支付證券的現金。此次出售是在過去三個月的上一筆交易之後進行的，當時戴維斯出售了15萬股股票，總收益爲18,872,130美元。
默沙東公司根據最近的一份文件，公司高管羅伯特·戴維斯定於2024年2月14日出售該公司85,021股普通股。這些股票的總市值爲10,661,573.89美元，於同日通過行使註冊計劃下的期權收購。該交易涉及向發行人支付證券的現金。此次出售是在過去三個月的上一筆交易之後進行的，當時戴維斯出售了15萬股股票，總收益爲18,872,130美元。
有用
沒用